WINDOW OF OPPORTUNITY STUDY ASSESSING NIVOLUMAB AND IPILIMUMAB IN PEOPLE WITH NEUROFIBROMATOSIS TYPE 1 AND NEWLY DIAGNOSED MALIGNANT AND PREMALIGNANT PERIPHERAL NERVE SHEATH TUMORS
$1,093,044FY2022Defense Health AgencyDOD
The Johns Hopkins University